Professor Jonathan Heeney

Cambridge vaccine expert in $42million partnership to develop 'future-proofed' coronavirus vaccines

08 March 2022

Prime Minister Boris Johnson announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS.

Read More

Pages